Vincent L. Giranda

7.1k total citations
115 papers, 4.4k citations indexed

About

Vincent L. Giranda is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Vincent L. Giranda has authored 115 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Oncology, 61 papers in Molecular Biology and 18 papers in Cancer Research. Recurrent topics in Vincent L. Giranda's work include PARP inhibition in cancer therapy (59 papers), DNA Repair Mechanisms (27 papers) and PI3K/AKT/mTOR signaling in cancer (15 papers). Vincent L. Giranda is often cited by papers focused on PARP inhibition in cancer therapy (59 papers), DNA Repair Mechanisms (27 papers) and PI3K/AKT/mTOR signaling in cancer (15 papers). Vincent L. Giranda collaborates with scholars based in United States, United Kingdom and Canada. Vincent L. Giranda's co-authors include Yan Luo, Xuesong Liu, Yan Shi, Eric F. Johnson, Jennifer J. Bouska, V. Nienaber, Keith W. Woods, Thomas D. Penning, Vered Klinghofer and Kent D. Stewart and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Vincent L. Giranda

114 papers receiving 4.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Vincent L. Giranda United States	40	2.5k	2.1k	598	552	402	115	4.4k
Christine Lukacs United States	21	3.9k 1.5×	2.5k 1.2×	625 1.0×	637 1.2×	257 0.6×	35	5.3k
Zoran Filipovic United States	10	3.9k 1.5×	3.2k 1.5×	608 1.0×	695 1.3×	352 0.9×	17	5.3k
Emily A. Liu United States	5	2.9k 1.1×	2.3k 1.1×	448 0.7×	489 0.9×	225 0.6×	5	3.9k
Nader Fotouhi United States	19	3.3k 1.3×	2.3k 1.1×	629 1.1×	547 1.0×	213 0.5×	47	4.7k
Binh Thanh Vu Vietnam	17	4.2k 1.6×	3.4k 1.6×	742 1.2×	733 1.3×	355 0.9×	48	5.8k
Moulay A. Alaoui‐Jamali Canada	42	3.1k 1.2×	1.3k 0.6×	332 0.6×	792 1.4×	333 0.8×	138	4.8k
Sandra B. Gabelli United States	34	3.6k 1.4×	1.7k 0.8×	313 0.5×	253 0.5×	293 0.7×	100	5.4k
Ouathek Ouerfelli United States	33	2.7k 1.1×	1.2k 0.5×	527 0.9×	406 0.7×	950 2.4×	62	4.1k
Michelle M. Lilly United States	38	2.4k 0.9×	1.3k 0.6×	394 0.7×	573 1.0×	471 1.2×	103	4.4k
Min H. Kang United States	38	3.6k 1.4×	1.7k 0.8×	188 0.3×	689 1.2×	640 1.6×	140	5.2k

Countries citing papers authored by Vincent L. Giranda

Since Specialization

Citations

This map shows the geographic impact of Vincent L. Giranda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vincent L. Giranda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vincent L. Giranda more than expected).

Fields of papers citing papers by Vincent L. Giranda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vincent L. Giranda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vincent L. Giranda. The network helps show where Vincent L. Giranda may publish in the future.

Co-authorship network of co-authors of Vincent L. Giranda

This figure shows the co-authorship network connecting the top 25 collaborators of Vincent L. Giranda. A scholar is included among the top collaborators of Vincent L. Giranda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vincent L. Giranda. Vincent L. Giranda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Armstrong, Andrew J., Ravit Geva, Hyun Cheol Chung, et al.. (2024). CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial. Investigational New Drugs. 42(1). 145–159. 33 indexed citations

Bessudo, Alberto, Abdul Haseeb, James A. Reeves, et al.. (2024). Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Microsatellite Stable Colorectal Cancer. Clinical Colorectal Cancer. 23(3). 285–294. 4 indexed citations

Rodler, Eve T., Brenda F. Kurland, Melissa Griffin, et al.. (2016). Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer. Clinical Cancer Research. 22(12). 2855–2864. 69 indexed citations

Ramalingam, Suresh S., Normand Blais, Julien Mazières, et al.. (2016). Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research. 23(8). 1937–1944. 65 indexed citations

Mehta, Minesh P., Ding Wang, Fen Wang, et al.. (2015). Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study. Journal of Neuro-Oncology. 122(2). 409–417. 75 indexed citations

Mostafa, Nael M., et al.. (2014). A phase 1 study to evaluate effect of food on veliparib pharmacokinetics and relative bioavailability in subjects with solid tumors. Cancer Chemotherapy and Pharmacology. 74(3). 583–591. 11 indexed citations

Shi, Yan, Larry R. Solomon, Vincent L. Giranda, et al.. (2011). Ubiquitin-specific Cysteine Protease 2a (USP2a) Regulates the Stability of Aurora-A. Journal of Biological Chemistry. 286(45). 38960–38968. 58 indexed citations

Isakoff, SJ, Beth Overmoyer, Nadine Tung, et al.. (2010). A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.. Journal of Clinical Oncology. 28(15_suppl). 1019–1019. 122 indexed citations

Palma, Joann P., Yichun Wang, Luis E. Rodrı́guez, et al.. (2009). ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors. Clinical Cancer Research. 15(23). 7277–7290. 111 indexed citations

10.

Liu, Xuesong, Edward K. Han, Mark G. Anderson, et al.. (2009). Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways. Molecular Cancer Research. 7(10). 1686–1692. 77 indexed citations

11.

Molina, Julian R., et al.. (2009). Abstract #3602: Ongoing phase 1 study of a novel PARP inhibitor, ABT-888 in combination with temozolamide; Pharmacokinetics, safety and anti-tumor activity. Cancer Research. 69. 3602–3602. 2 indexed citations

12.

Yang, Sherry X., Shivaani Kummar, Seth M. Steinberg, et al.. (2009). Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biology & Therapy. 8(21). 2004–2009. 21 indexed citations

13.

Han, Edward K., Thomas McGonigal, Christopher Butler, Vincent L. Giranda, & Yan Luo. (2008). Characterization of Akt overexpression in MiaPaCa-2 cells: prohibitin is an Akt substrate both in vitro and in cells.. PubMed. 28(2A). 957–63. 39 indexed citations

14.

Liu, Xuesong, Yan Shi, Ran Guan, et al.. (2008). Potentiation of Temozolomide Cytotoxicity by Poly(ADP)Ribose Polymerase Inhibitor ABT-888 Requires a Conversion of Single-Stranded DNA Damages to Double-Stranded DNA Breaks. Molecular Cancer Research. 6(10). 1621–1629. 61 indexed citations

15.

Zhu, Gui‐Dong, Jianchun Gong, Viraj B. Gandhi, et al.. (2007). Design and synthesis of pyridine–pyrazolopyridine-based inhibitors of protein kinase B/Akt. Bioorganic & Medicinal Chemistry. 15(6). 2441–2452. 58 indexed citations

16.

Guan, Ran, Paul Tapang, Joel Johansson, et al.. (2005). Small Interfering RNA–Mediated Polo-Like Kinase 1 Depletion Preferentially Reduces the Survival of p53-Defective, Oncogenic Transformed Cells and Inhibits Tumor Growth in Animals. Cancer Research. 65(7). 2698–2704. 122 indexed citations

17.

Luo, Yan, Mary K. Joseph, Christopher Butler, et al.. (2001). Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents.. PubMed. 21(1A). 23–8. 28 indexed citations

18.

Giranda, Vincent L., Xiang‐Peng Kong, David Egan, et al.. (1996). The crystal structure of the human papillomavirus 31 E2 DNA binding domain in the absence of DNA. Acta Crystallographica Section A Foundations of Crystallography. 52(a1). C156–C156. 5 indexed citations

19.

Giranda, Vincent L.. (1994). Structure-based drug design of antirhinoviral compounds. Structure. 2(8). 695–698. 4 indexed citations

20.

Giranda, Vincent L., Helen M. Berman, & Vern L. Schramm. (1989). Crystallographic Quaternary Structural Analysis of AMP Nucleosidases from Escherichia coli and Azotobacter vinelandii. Journal of Biological Chemistry. 264(26). 15674–15680. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact